Spontaneous bacterial peritonitis: Difference between revisions

From IDWiki
()
No edit summary
 
(6 intermediate revisions by the same user not shown)
Line 1: Line 1:
  +
==Background==
= Definition =
 
   
* Primary infection of the ascitic fluid
+
*Primary infection of the ascitic fluid, diagnosed by ascites fluid with positive culture or with neutrophil count greater than 250
   
  +
===Microbiology===
= Pathophysiology =
 
   
 
*''[[Escherichia coli]]'' (43%)
* Intestinal bacterial overgrowth with increased intestinal permeability leads to translocation to intestinal lymph notes and bloodstream, which results in hematogenous seeding to ascitic fluid
 
 
*''[[Klebsiella pneumoniae]]'' (11%)
* Only occurs in portal hypertension, not in other causes of ascites
 
  +
*''[[Streptococcus pneumoniae]]'' (9%), particularly affecting people with [[HIV]] and prepubertal girls
 
*Other streptococcal species (19%)
 
*Enterobacteriaceae (4%)
 
*''[[Staphylococcus]]'' (3%)
 
*''[[Pseudomonas]]'' (1%)
 
*Miscellaneous (10%)
 
**''[[Aeromonas hydrophila]]'', in Korea
  +
**[[Peritoneal tuberculosis]]
  +
**[[Dimorphic fungi]]
   
 
===Pathophysiology===
= Bacteriology =
 
   
 
*Intestinal bacterial overgrowth with increased intestinal permeability leads to translocation to intestinal lymph notes and bloodstream, which results in hematogenous seeding to ascitic fluid
* ''Escherichia coli'' (43%)
 
 
*Only occurs in portal hypertension, not in other causes of ascites
* ''Klebsiella pneumoniae'' (11%)
 
* ''Streptococcus pneumoniae'' (9%)
 
* Other streptococcal species (19%)
 
* Enterobacteriaceae (4%)
 
* ''Staphylococcus'' (3%)
 
* ''Pseudomonas'' (1%)
 
* Miscellaneous (10%)
 
** ''Aeromonas hydrophila'', in Korean
 
   
= Risk Factors =
+
===Risk Factors===
   
* Previous history of SBP
+
*Previous history of SBP
* Upper GI bleed
+
*[[Upper GI bleed]]
* Low sciatic protein
+
*Low sciatic protein
* Child-Pugh class
+
*Child-Pugh class
   
  +
==Clinical Manifestations==
= Presentation =
 
   
* Asymptomatic in 10%
+
*Asymptomatic in 10%
* Fever (70%)
+
*Fever (70%)
* Abdominal pain (60%)
+
*Abdominal pain (60%)
* Hepatic encephalopathy (50%)
+
*Hepatic encephalopathy (50%)
* Abdominal tenderness, usually without rigidity (50%)
+
*Abdominal tenderness, usually without rigidity (50%)
* Diarrhea (30%)
+
*Diarrhea (30%)
* Ileus (30%)
+
*Ileus (30%)
* Shock (20%)
+
*Shock (20%)
* Hypothermia (15%)
+
*Hypothermia (15%)
   
  +
===Variants===
= Investigations =
 
   
  +
*'''Culture-negative neutrocytic ascites:''' usually caused by difficult-to-treat organisms like tuberculosis, and non-infective sources
* Labs
 
  +
*'''Monomicrobial non-neutrocytic bacterascites:''' early bacterial colonization
** Ascitic fluid for cell count and culture
 
  +
*'''Polymicrobial bacterascites:''' usually from traumatic paracentesis
*** Neutrophil count < 250 rules it out
 
*** Culture usually monomicrobial
 
** Repeat paracentesis at 48h if ongoing concern
 
* Imaging
 
* Other
 
   
  +
===Prognosis and Complications===
= Management =
 
   
 
*In-hospital mortality of about 33% in hospital
* Acute
 
 
*58% 6-month mortality
** Ceftriaxone 1-2g IV q24h
 
* Chronic
 
** Prophylaxis after a single episode
 
*** Septra SS PO daily
 
*** Norfloxacin
 
* Some role for primary prophylaxis, I think?
 
   
 
==Investigations==
= Prognosis =
 
   
  +
*Diagnostic paracentesis with ascitic fluid sent for cell count with differential and culture
* In-hospital mortality of about 33% in hospital
 
 
**Neutrophil count < 250 rules it out
* 58% 6-month mortality
 
 
**Culture usually monomicrobial
 
*Repeat paracentesis at 48h if ongoing concern
  +
 
==Management==
  +
  +
*[[Is treated by::Ceftriaxone]] 1-2g IV q24h + [[albumin]] 1.5 g/kg on day 1 and 1 g/kg on day 3
  +
  +
==Prevention==
  +
 
*Prophylaxis is indicated after even a single episode of SBP
 
**[[TMP-SMX]] SS or DS PO daily
  +
**[[Norfloxacin]] 400 mg PO daily
  +
**[[Ciprofloxacin]] 500 mg PO daily
  +
**[[Doxycycline]] 100 mg PO daily is under investigations as an alternative<ref>Doxycycline for the prevention of spontaneous bacterial peritonitis. Abstract presented at the AASLD Liver Meeting 2020. Available at: https://aasld.confex.com/aasld/2020/meetingapp.cgi/Paper/19190</ref>
 
*Possibly a role for primary prophylaxis
   
 
[[Category:Intra-abdominal infections]]
 
[[Category:Intra-abdominal infections]]

Latest revision as of 15:58, 1 December 2023

Background

  • Primary infection of the ascitic fluid, diagnosed by ascites fluid with positive culture or with neutrophil count greater than 250

Microbiology

Pathophysiology

  • Intestinal bacterial overgrowth with increased intestinal permeability leads to translocation to intestinal lymph notes and bloodstream, which results in hematogenous seeding to ascitic fluid
  • Only occurs in portal hypertension, not in other causes of ascites

Risk Factors

  • Previous history of SBP
  • Upper GI bleed
  • Low sciatic protein
  • Child-Pugh class

Clinical Manifestations

  • Asymptomatic in 10%
  • Fever (70%)
  • Abdominal pain (60%)
  • Hepatic encephalopathy (50%)
  • Abdominal tenderness, usually without rigidity (50%)
  • Diarrhea (30%)
  • Ileus (30%)
  • Shock (20%)
  • Hypothermia (15%)

Variants

  • Culture-negative neutrocytic ascites: usually caused by difficult-to-treat organisms like tuberculosis, and non-infective sources
  • Monomicrobial non-neutrocytic bacterascites: early bacterial colonization
  • Polymicrobial bacterascites: usually from traumatic paracentesis

Prognosis and Complications

  • In-hospital mortality of about 33% in hospital
  • 58% 6-month mortality

Investigations

  • Diagnostic paracentesis with ascitic fluid sent for cell count with differential and culture
    • Neutrophil count < 250 rules it out
    • Culture usually monomicrobial
  • Repeat paracentesis at 48h if ongoing concern

Management

Prevention

  • Prophylaxis is indicated after even a single episode of SBP
  • Possibly a role for primary prophylaxis
  1. Doxycycline for the prevention of spontaneous bacterial peritonitis. Abstract presented at the AASLD Liver Meeting 2020. Available at: https://aasld.confex.com/aasld/2020/meetingapp.cgi/Paper/19190